Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239167 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2GLAALDH1A1LMNAMTNR1A | |
| SCHEMBL20239352 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2GLAALDH1A1LMNAMTNR1A | |
| SCHEMBL20239270 | 0.84 | CA1 (0.46) | SMN1; SMN2GLAALDH1A1LMNA | |
| SCHEMBL20239194 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2GLAMTNR1AMTNR1BACACB | |
| SCHEMBL20239276 | 0.77 | LOXL2 (0.48) | SMN1; SMN2GLAALDH1A1KMT2APTPN1 | |
| SCHEMBL20239158 | 0.75 | EPHX2 (0.43) | SMN1; SMN2GLAALDH1A1ACACBKMT2A | |
| SCHEMBL659053 | 0.74 | SMN1; SMN2 (1.00) | SMN1; SMN2GLAALDH1A1LMNAMTNR1A | |
| SCHEMBL20252436 | 0.73 | LOXL2 (0.43) | SMN1; SMN2GLAKMT2ANPC1 | |
| SCHEMBL20239168 | 0.73 | RAB9A (0.47) | SMN1; SMN2ALDH1A1ACACBKMT2ANPC1 | |
| SCHEMBL20239177 | 0.72 | DGAT2 (0.49) | SMN1; SMN2ALDH1A1MTNR1AMTNR1BACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | SMN1; SMN2 4828/4885GLA 267/4885ALDH1A1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.